During fires, L.A. burn centers braced for crisis that never came
When the fires erupted Jan. 7, burn centers across the Los Angeles region braced for an influx of patients, updating one ...
Contract Pharma4d
AbbVie’s EMBLAVEO Approved by FDA for Treatment of Complicated Intra-Abdominal Infections
Addresses the significant threat of antimicrobial resistance.
Managed Healthcare Executive4d
FDA Approves Combination Antibiotic for Complicated Infections
Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.
Pharm Exec3d
FDA Approves AbbVie’s Emblaveo for Complicated Intra-Abdominal Infections
Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...
Daily Breeze1d
Things to do on and around the Palos Verdes Peninsula, Feb. 13-19
Wandering Jews Hike: Saturday afternoon hikes in Palos Verdes. Most hikes are easy or moderate, take 1-2 hours and start at 2 ...
Daily6d
AbbVie gets USFDA nod for Emblaveo for treatment of adults with complicated intra abdominal infections with limited or no treatment option
AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as a ...
FiercePharma4d
AbbVie scores FDA nod for Pfizer-partnered antibiotic Emblaveo
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
Daily11h
FDA approves drug combination for complicated intra-abdominal infections
AbbVie announced that the US FDA has approved aztreonam and avibactam (Emblaveo), in combination with metronidazole, for ...